Procurement of storage and stability services to maintain BARDA’s supply of Live Attenuated Influenza Virus Master and Working Seed Lots
ID: 75A50125Q00001Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSEASPR BARDA DIV CONTRACTS MGMT & ACQWashington, DC, 20515, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/33b6c132da2744f8a17360a378dea6ad/view
Timeline
    Description

    The Department of Health and Human Services (HHS), specifically the Biomedical Advanced Research and Development Authority (BARDA), is seeking to procure storage and stability services for maintaining its supply of Live Attenuated Influenza Virus Master and Working Seed Lots. The procurement aims to ensure that these seed lots remain within specification for use in clinical trials or commercial drug production, which is critical for pandemic preparedness. The contract will be awarded on a sole source basis to MedImmune, LLC, which has been performing these services under a previous indefinite-delivery, indefinite-quantity contract since 2016. Interested parties may submit capability statements or quotations for consideration, and inquiries can be directed to Deitra Williams at deitra.williams@hhs.gov or Corneilus Stephens at corneilus.stephens@hhs.gov.

    Point(s) of Contact
    Deitra Williams
    (202) 845-4483
    deitra.williams@hhs.gov
    Corneilus Stephens
    (202) 738-0221
    corneilus.stephens@hhs.gov
    Files
    No associated files provided.
    Similar Opportunities
    Phase I - Serological Assays for the detection and characterization of influenza viruses
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking contractors for a Phase I project focused on developing serological assays for the detection and characterization of influenza viruses. The contract entails a 12-month base period with four additional 12-month option periods, aimed at testing immunological responses from human samples collected during vaccine effectiveness studies and outbreak investigations using Hemagglutination Inhibition (HAI) assays. This initiative is critical for enhancing the understanding of influenza vaccine efficacy and ensuring public health safety. Interested parties can contact Jennifer Gartzke at jgartzke@cdc.gov or by phone at 404-498-0020 for further details, as this opportunity is open for full competition due to previous insufficient small business participation.
    Storage of NHANES Biospecimen Samples
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking proposals for the storage and management of approximately 500,000 biospecimen samples from the National Health and Nutrition Examination Survey (NHANES). The contractor will be responsible for receiving, securely storing, inventorying, and shipping these samples, while ensuring compliance with health regulations and maintaining the integrity of the samples throughout the contract period from March 15, 2025, to March 14, 2030. This procurement is critical for supporting future health research and maintaining public health data integrity, with a focus on quality assurance and confidentiality. Interested small businesses must submit proposals electronically, adhering to specific guidelines, with the solicitation anticipated to be posted on SAM.gov around December 9, 2024. For further inquiries, potential bidders can contact Amy Holder at zts0@cdc.gov or Arianna Williams at xsm2@cdc.gov.
    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Broad Agency Announcement (BAA) BAA-23-100-SOL-00004 for advanced research and development of Medical Countermeasures (MCMs) aimed at addressing public health threats such as chemical, biological, radiological, and nuclear (CBRN) incidents, as well as emerging infectious diseases and pandemic influenza. The initiative seeks to foster public-private partnerships to enhance the development and responsiveness of life-saving MCMs, emphasizing the importance of technological maturity, regulatory compliance, and manufacturing standards in the evaluation process. This opportunity is critical for strengthening national health security and improving preparedness for future public health emergencies, with an open submission period running until September 25, 2028, at 4:30 PM Eastern Time. Interested parties can direct inquiries to BARDA-BAA@hhs.gov for further information.
    Online recruitment campaign for an influenza virus seasonal epidemic and pandemic Phase 1 study
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through its National Institute of Allergy and Infectious Diseases (NIAID), intends to negotiate a sole-source contract with BuildClinical, LLC for an online recruitment campaign related to a Phase 1 clinical study of a novel influenza vaccine. The primary objective of this procurement is to effectively recruit healthy adult participants for a clinical trial evaluating the safety, tolerability, and immunogenicity of the mosaic hexavalent influenza vaccine VRC-FLUMOS0116-00-VP, with and without an adjuvant, to address the significant public health challenge posed by seasonal and pandemic influenza. This initiative is crucial as influenza continues to result in substantial morbidity and mortality, and the development of a universal vaccine is a priority for public health. Interested parties may submit capability statements via the NIH electronic Simplified Acquisition Submission System (eSASS) by January 3, 2025, at 5:00 PM ET, with all submissions requiring registration in the eSASS system. For further inquiries, Dana Monroe can be contacted at dana.monroe@nih.gov or by phone at 406-375-9814.
    Ongoing Monoclonal Antibodies and Plasmids Services through GENSCRIPT
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), intends to negotiate a sole-source contract with GenScript USA Inc. for ongoing monoclonal antibodies and plasmids services. The procurement aims to support the NIAID Laboratory of Immunogenetics (LIG) in advancing research on human B cells and the isolation of monoclonal antibodies, which are critical for developing new vaccine candidates against influenza. This contract is a continuation of existing services that require continuity for accurate comparison of results, and interested parties may submit capability statements via the NIAID electronic Simplified Acquisition Submission System (eSASS) by January 3, 2025, at 5:00 PM ET. For further inquiries, contact Dana Monroe at dana.monroe@nih.gov or call 406-375-9814.
    BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Office of Biomedical Advanced Research and Development Authority (BARDA), is soliciting proposals under the Easy Broad Agency Announcement (EZ-BAA) BAA-22-100-SOL-00003, which focuses on innovative medical countermeasures (MCMs) to enhance public health preparedness against various threats, including infectious diseases and chemical agents. The initiative invites submissions across multiple Areas of Interest (AOIs), including but not limited to vaccine innovations, diagnostic technologies, and therapeutic solutions for acute radiation syndrome and chemical threats. This opportunity is critical for advancing biomedical research and developing effective responses to health emergencies, with multiple awards anticipated based on scientific merit and funding availability. Interested parties must register on SAM.gov and submit their abstracts by specified deadlines, with key submission dates ranging from March 15, 2024, to May 31, 2024, depending on the AOI. For further inquiries, respondents can contact Aarati Singal or Lara Emmons at DRIVeAcquisitions@hhs.gov.
    CDC DFWED NARST Sensititre Supplies
    Active
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) is seeking to award a sole source contract for antimicrobial resistance testing supplies, specifically Sensititre™ broth microdilution testing products, from ThermoFisher Scientific. This procurement is essential for the National Antimicrobial Resistance Monitoring System (NARMS), which has utilized these proprietary materials since 1996 to ensure a standardized approach to monitoring enteric bacteria resistance. The unique nature of these supplies necessitates this sole source approach, as alternatives would require significant investments in new equipment and validation processes, potentially disrupting critical surveillance efforts. Interested parties may respond within 15 days to express their interest, with proposals directed to contract specialist Ashley Williams at dal3@cdc.gov.
    Orbitor RS2 Microplate Robotic Bundle with Software
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through its National Institute of Allergy and Infectious Diseases (NIAID), intends to procure an Orbitor RS2 Microplate Robotic Bundle with integrated software for its Vaccine Immunology Program (VIP) within the Vaccine Research Center (VRC). This procurement aims to automate the handling and analysis of Mabtech Fluorospot Assays, which are critical for evaluating T-cell responses in clinical trials, thereby enhancing the efficiency and accuracy of vaccine research. The equipment must meet specific technical requirements, including compatibility with existing lab systems and advanced features such as a bi-directional telescoping arm and Momentum™ scheduling software. Interested vendors are invited to submit capability statements via the NIAID electronic Simplified Acquisition Submission System (eSASS) by January 3, 2025, at 5:00 PM ET, with all submissions considered by the Government at its discretion.
    Public Health Industrial Base Capabilities and Capacities: Anti-Microbials
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services (HHS) is seeking industry partners to provide information regarding domestic production capabilities related to anti-microbials under the Defense Production Act Title III Program. The objective of this Request for Information (RFI) is to identify gaps in the Public Health Industrial Base (PHIB) and enhance national defense resources by focusing on the production of essential medicines and medical countermeasures sourced domestically. Respondents are encouraged to share insights on their manufacturing processes, regulatory compliance, and infrastructure, as well as past supply chain disruptions and investment needs, with responses due by January 6, 2025, at 10 AM ET. Interested parties should submit their responses to Chris Newell at IBMSC-Submissions@hhs.gov.
    MRC Biosafety Cabinet Evaluation
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the Food and Drug Administration (FDA), is seeking qualified small businesses to provide engineering evaluation services for biological safety cabinets (BSCs) at its Center for Veterinary Medicine. The primary objective of this procurement is to assess existing BSCs that are failing to meet certification standards, particularly focusing on their associated HVAC and control systems, and to provide recommendations for replacements. This evaluation is crucial for maintaining laboratory safety and operational efficiency, ensuring compliance with federal safety standards. Interested parties must attend a mandatory site visit on December 17, 2024, and submit their quotations by January 8, 2025, to the contracting officer, Sheneil Green, at Sheneil.Green@fda.hhs.gov.